SOLANA BEACH, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti® (metoclopramide) nasal spray, reaffirms its commitment to improving the lives of patients suffering from diabetic gastroparesis in light of the recent decision by the U.S. Food and Drug Administration (FDA) to not approve Vanda Pharmaceuticals new drug application (NDA) for Tradipitant, an ...

SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that management will participate in the Gastroenterology and Hepatology Advanced Practice Providers Conference taking place from September 12 – 14, 2024 at the Gaylord National Resort Convention Center in National Harbor, Maryland. “As a meeting spon ...

公司概况 - 公司推出了首个也是唯一一个用于治疗成人急性和复发性糖尿病胃轻瘫症状的鼻喷剂Gimoti[55] - Gimoti于2020年6月获得FDA批准上市[55] - 公司与Eversana签订商业服务协议,由Eversana负责Gimoti在美国的商业化和销售[55,56] - 公司于2020年10月开始在美国销售Gimoti[55] 产品表现 - 公司报告称糖尿病胃轻瘫患者使用Gimoti相比使用口服甲氧氯普胺,就诊次数、急诊就诊次数和住院次数显著减少,从而降低了约1.5万美元的患者和支付方成本[55] - 公司2024年第二季度Gimoti销售净额约2.6百万美元,较上一季度增加0.9百万美元[60] - 公司将Gimoti处方服务从vitaCare过渡到ASPN,提高了保险支付比例[60] - 新增药房也增加了冗余性和处方的填写能力,减少了依赖单一药房合作伙伴[61] - 公司现在以更快的速度处理入院处方,显示患者捕获和转换为保险公司报销的处方有所改善,并减少了对优惠计划的依赖[61] - 2024年6月30日结束的季度内,公司的报销中心收到约1,718个新的入院处方,比2024年3月31日结束的季度增加约20%[61] - 与2024年3月31日结束的季度相比,患者完成自付额抵扣后,公司的自付费用支出大幅下降,导致获得保险报销的处方比例增加[61] - 有机会重复购买该产品的患者(即完成首次购买并有额外重复购买处方的患者)约71%会进行重复购买[61] - 2024年6月30日结束的季度内,新开具处方医生数量累计增加12%[61] - 政府医疗保险计划(Medicare和Medicaid)在2024年上半年占Gimoti处方量的约34%[62] - 自Gimoti上市以来至2024年6月30日,大多数患者年龄在31-65岁之间,绝大多数为女性,由胃肠病专科医生或其护士执业助理开具处方[62] - 关键意见领袖积极展示Gimoti的安全性数据,显示与既往发表的数据相比,其致迟发性运动障碍的发生率大幅降低[62] 融资情况 - 公司于2024年2月完成6.2百万美元的股权融资,有助于满足纳斯达克最低股东权益要求[57] - 公司于2024年8月1日实施12比1的反向股票拆分,以满足纳斯达克最低股价要求[58] - 公司自成立以来主要通过出售股权证券和借款为运营提供资金[75] - 公司与Eversana签订协议,获得最高500万美元的循环信贷额度,该信贷额度将于2026年12月31日到期[75] - 公司于2024年2月进行公开发行,共发行42.79万股普通股和49.12万份预付款认股权证,募集资金净额约620万美元[75] - 公司在2024年上半年共有20.22万份系列B认股权证被行权,为公司带来约150万美元的净收入[75] 持续经营能力 - 公司认为存在持续经营能力的重大不确定性,预计现有现金和现金等价物将可支持公司运营至2025年第二季度[75,76] - 公司预计将继续发生费用,包括Gimoti的商业化活动、生产、进行单剂PK临床试验以及维护知识产权等[76,78] - 公司未来资金需求的金额和时间将取决于多方面因素,包括商业化活动成本、Gimoti的商业成功、生产能力、临床试验进展等[78] - 公司作为小报告公司无需提供市场风险的定量和定性披露[78]

SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that its board of directors (Board) has approved a 1-for-12 reverse stock split of the company's common stock. The reverse stock split will become effective at 12:01 a.m. Eastern time on August 1, 2024. The company's common stock is expected to b ...

Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced updates regarding their business and commercial growth strategy. With ...

Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced updates regarding their business and commercial growth strategy. With ...

SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that its abstract demonstrating enhanced gastroparesis care in women using nasal metoclopramide will be presented at the 2024 Digestive Disease Week Conference (DDW 2024) taking place May 18-21, 2024 in Washington D.C. "Being patient-centric is at the c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-36075 EVOKE PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-8447886 (State or other jurisdiction (IRS Employer of incorporation) I ...

SOLANA BEACH, Calif., April 17, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced it will host a virtual KOL and investor webinar on Wednesday, April 24 at 12:00 p.m. ET. Moderated by Yale Jen, PhD, Senior Managing Director of Equity Research at Laidlaw Capital Markets, the event will feature Michael Cline, DO., Medical Director Ga ...

公司任命 - Evoke Pharma, Inc.宣布Matthew J. D'Onofrio将接替David A. Gonyer成为首席执行官[1] 使命宣言 - Matthew J. D'Onofrio表示将继续致力于推广GIMOTI治疗糖尿病胃轻瘫的使命[2] 公司业务 - Evoke Pharma专注于治疗胃肠道疾病，已成功开发并推出GIMOTI鼻喷剂[3]